Mammary Cell News Volume 8.18 | May 12 2016

Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism
To delineate the functional outcome of chromosome 8p loss of heterozygosity (LOH), a common aberration in breast cancer, scientists modeled 8p LOH using TALEN-based genomic engineering. [Cancer Cell] Full Article | Graphical Abstract

UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple Negative Breast Cancer
Researchers hypothesized that binding the inactive kinase conformation would lead to improved pharmacological outcomes by altering the non-catalytic functions of the targeted kinases. [Clin Cancer Res] Abstract

MiR-16 Mediates Trastuzumab and Lapatinib Response in ErbB-2-Positive Breast and Gastric Cancer via Its Novel Targets CCNJ and FUBP1
Investigators revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive breast cancer and gastric cancer. [Oncogene] Abstract

HOXA5 Determines Cell Fate Transition and Impedes Tumor Initiation and Progression in Breast Cancer through Regulation of E-Cadherin and CD24
The authors investigated cellular and molecular consequences of loss of HOXA5 in breast cancer, and the role played by retinoic acid in HOXA5 function. [Oncogene] Abstract

Identification of Selective Cytotoxic and Synthetic Lethal Drug Responses in Triple Negative Breast Cancer Cells
Scientists aimed to understand the functional differences of triple negative breast cancer (TNBC) subtypes and how they may relate to potential novel therapeutic strategies, they studied comprehensive anticancer-agent responses among a panel of TNBC cell lines. [Mol Cancer] Full Article

An Integrated Cell Line-Based Discovery Strategy Identified Follistatin and Kallikrein 6 as Serum Biomarker Candidates of Breast Carcinoma
Investigators compared the secretome of a series of four genetically-related breast cancer cell lines as a model of aggressiveness using quantitative mass spectrometry. 537 proteins predicted to be released or shed from cells were identified. [J Proteomics] Abstract

Breast Cancer Gene Therapy Using an Adenovirus Encoding Human IL-2 Under Control of Mammaglobin Promoter/Enhancer Sequences
Scientists have determined whether transcriptional targeting of interleukin-2 (IL-2) to breast cancer using an engineered human mammaglobin promoter/enhancer is a feasible option for reducing IL-2-associated toxicities while still achieving a meaningful antitumor effect. [Cancer Gene Ther] Abstract

CLINICAL RESEARCH

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared with No Systemic Treatment in Premenopausal Patients with Primary Breast Cancer: Long-Term Follow-Up (> 25 Years) of the Phase III SBII:2pre Trial
Researchers evaluated the long-term effect of two years of adjuvant tamoxifen compared with no systemic treatment (control) in premenopausal patients with breast cancer over different time periods through long-term follow-up. [J Clin Oncol] Full Article

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
The trial determined the recommended Phase II dose and clinical efficacy of the src-kinase inhibitor dasatinib combined with zoledronic acid in bone predominant, HER2-negative breast cancer metastases. [Clin Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Concure Oncology^® Launches One-Time, One-Day Radiation Treatment for Early-Stage Breast Cancer
Concure Oncology/Breast Microseed, Inc. announces the launch of its one-time, one-hour radiation treatment option for early-stage breast cancer. Breast Microseed Treatment makes a quicker return to normal activity possible for post-lumpectomy patients by offering a simple, more convenient outpatient procedure. [Concure Oncology/Breast Microseed, Inc. (2016 PR Newswire Association LLC)] Press Release

Innocrin Pharmaceuticals, Inc. Begins Phase II Study of Seviteronel in Women with Estrogen Receptor-Positive or Triple-Negative Breast Cancer
Innocrin Pharmaceuticals, Inc. announced that they have started dosing in a Phase II study of women with estrogen receptor-positive or triple-negative breast cancer. The Phase I portion of the seviteronel study has completed and a once-daily dose was selected for advancement into Phase II development. [Innocrin Pharmaceuticals, Inc.] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM. Watch the webinar.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Fellow(s) – Various Projects (National University of Singapore)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Research Associate – Cell Biology in Breast Cancer (University of South Australia)

Research Associate – Various Medical Disciplines (Jinan University)

Part-Time Researcher – Molecular Markers in Breast Cancer (University of Bergen)

Postdoctoral Fellow – RNA Splicing in Breast Cancer (Memorial Sloan Kettering Cancer Center)

Scientist – Cancer Research (Institute of Clinical Physiology)

Postdoctoral Fellow – Metastatic Reactivation of Cancer (MD Anderson Cancer Center)

Faculty Position – Cancer Immunology (University of New Mexico)

Faculty Position – Cancer Research (Eppley Institute for Research in Cancer)

Postdoctoral Fellow – Breast Cancer (Northwestern University)

Faculty Position – Tumor Immunology (John Wayne Cancer Institute at Providence Saint John’s Health Center)

Postdoctoral Fellow – Noncoding RNAs in Breast Cancer (University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow – Breast and Ovarian Cancer (Johns Hopkins University School of Medicine)

Postdoctoral Fellowship – Platelets in Metastatic Breast and Colon Cancer (Université de Strasbourg)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.